Abstract: Cell lines have been produced that secrete monoclonal antibodies capable of binding to the flagellar proteins of selected Pseudomonas aeruginosa strains. Some of these antibodies have been found to be protective against lethal challenges of P. aeruginosa. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.Prior to filing this application, the continuous transformed cell lines PaF4 IVE8, FA6 IIG5, 20H11, and 21B8, described herein, were deposited in the America Type Culture Collection and given the designations HB9129, HB9130, CRL 9300, and CRL 9301, respectively.

Abstract: A method of expressing peptides which are immunologically reactive with antibodies to LAV is disclosed. The peptides are produced by bacterial host cells transformed with a recombinant plasmid which includes appropriate procaryotic transcriptional and translational signals for expression, followed by a DNA sequence coding for a peptide comprising the amino acid sequence as shown in FIG. 5 starting with isoleucine, number 1, and ending with threonine, number 173. The peptides of the present invention are immunologically reactive with antibodies to LAV, or antibodies to viruses defined to be the same as or equivalent to LAV. The peptides produced by the method disclosed may be used to screen for the presence of antibodies to LAV in a biological fluid, to determine the presence of LAV antigen in a biological fluid, or within a method for producing antibodies to LAV through the immunization of an animal with the peptide.

Abstract: An immunoassay in which a thermally induced phase separation is used to effect the separation of specifically bound reactants from free reactants is disclosed. A first reactant is conjugated to a temperature-sensitive polymer to form a polymer/reactant conjugate, and a second reactant is conjugated to a reporter to form a reporter/reactant conjugate. The polymer/reactant, reporter/reactant, and biological fluid samples suspected of containing the analyte are admixed in solution at a temperature other than that at which the polymer will precipitate. Specific binding is allowed to occur, thereby forming a ternary complex. The salt concentration of the adjusted solution is then adjusted to a concentration sufficient to cause the complex to precipitate from the solution, the amount of reporter activity in the precipitated complex or in the solution measured and the presence and/or concentration of the analyte therefrom determined.

Abstract: Conjugate monomers, polymers, and methods for the de novo synthesis of the polymers are provided. Conjugate organic monomers contain binding-pair members which upon polymerization become integrally associated with the resultant polymer. Specifically, antigens, antibodies, receptors, and ligands may be bound to organic monomers either directly by chemical reaction or indirectly by chemical spacer arms, and these conjugates may be polymerized or copolymerized with nonderivatized monomers to form polymers containing variable amounts of the binding-pair members. Such conjugate monomers and polymers find a wide variety of uses in binding to their binding-pair-member cognate which include selective removal of complementary binding-pair members from solution as well as in immunoassay procedures and in immunization regimes.

Abstract: Methods and compounds are disclosed for determining the presence, amount of, or association between substances of interest in samples suspected of containing same. The methods are based on the polymerization-induced separation of specifically-bound, reporter-labeled recognition reactants from free, reporter-labeled recognition reactants. The methods described are applicable to any substance for which suitable recognition reactants exist or can be made and are not limited by considerations such as chemical composition or molecular size.

Abstract: Immunoassay methods and compositions are disclosed for the detection of one or more analytes in fluid samples. The disclosure provides conjugates of analytes or reactants with polymerizable organic monomers. Specific binding reactions between reactants are detected by means of reporter/reactant conjugates. Free and specifically-bound reporter/reactant conjugates are separated by a polymerization reaction which renders the polymerized monomers insoluble.

Abstract: Methods and compositions are provided for determining a change in status of a multiple sclerosis victim. Particularly, the ratio of helper or suppressor T cell subsets having specific surface markers associated with proliferation is determined, where a particular ratio value is associated with a change in status.

Abstract: Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides in screening blood products.

Abstract: A method is disclosed for the de novo synthesis of antibody-containing polymers and the preparation of a class of polymerizable compounds used in the synthesis of such antibody-containing polymers. Antibody-containing polymers formed from monomer/antibody conjugates and nonderivatized polymerizable compounds can be varied in formation of the polymer to provide control of (a) molecular spacing, steric accessibility and the number of antibody molecules that are integrally incorporated into the polymer backbone, and (b) the chemical and physical structure of the polymer itself, thus enabling specific tailoring of antibody-containing polymers for particular end-use application. Also disclosed is a method for the selective removal of a compound from a solution or suspension thereof using monomer/receptor conjugates where the compound has the capacity to bind to the receptor in the conjugate.

Abstract: A method is disclosed for the de novo synthesis of polypeptide-containing polymers. This disclosure also includes a description of, and a method for the preparation of, a class of polymerizable compounds used in the synthesis of polypeptide-containing polymers. These polymerizable compounds are chemical conjugates prepared by covalent linkage of polymerizable organic monomers with specific polypeptides. Soluble monomer/polypeptide conjugates can be polymerized in solution with additional nonderivatized organic monomers to form desired polypeptide-containing polymers. The amount and composition of monomer and monomer/polypeptide conjugates can be varied in order to provide control of (a) molecular spacing, steric accessibility, and number of polypeptide molecules that are integrally incorporated into the polymer backbone, and (b) the chemical and physical structure of the polymer itself. This enables the specific tailoring of polypeptide-containing polymers for particular end-use applications.

Abstract: Novel method, cells and compositions are provided involving transforming B-lymphocytes to provide immortalization for continuous production of monoclonal antibodies to a predetermined ligand. T-cell free B-lymphocytes are combined with an Epstein-Barr virus transformed cell sensitive to a cytotoxic agent which does not significantly affect the B-lymphocytes under conditions where the sensitive EBV transformed cell acting as the transfer agent is killed and efficiently transforms the B-lymphocyte recipient cells with EBV. The EBV transformed B-lymphocyte cells are amplified and cloned, the desired clones isolated in accordance with conventional techniques and then used for production of monoclonal antibodies.